{"id":"71a6f879d198","type":"article","url":"https://hartvaat.nl/2026/09/29/diagnose-van-cardiale-amyloidose-blijft-vertraagd-in-egypte-hoge-sterfte-bij-pre/","title":"Diagnose van cardiale amyloïdose blijft vertraagd in Egypte — hoge sterfte bij presentatie","title_en":"Unraveling cardiac amyloidosis in Egypt: diagnostic challenges and disease outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology","doi":"10.1186/s43044-026-00784-x","source_url":"https://doi.org/10.1186/s43044-026-00784-x","authors":["Rasha Mohamed Abayazeed","Ingy Etman","Mahmoud Hassanein","Hagar Mahmoud Kamal","Mohamed Elsakhawy","Ahmed Abdelaaty","Maram Allam","Nouran Soror","Ashraf Elghandour","Mohamed H Elbahoty","Sara Salama","Osama Mohammed Refai","Noha Elkholy"],"significance":3,"published":"2026-10-07","source_date":"2026-09-29","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A single-center observational study of 70 confirmed cardiac amyloidosis patients in Egypt reveals a mean diagnostic delay of nearly 12 months and a high mortality rate of 48.6%. AL amyloidosis was the predominant subtype, accounting for the majority of cases, while ATTR represented only 4.3%. These findings highlight the critical need for heightened clinical awareness and streamlined diagnostic pathways to ensure earlier recognition and timely management of this progressive infiltrative cardiomyopathy.","created":"2026-09-30T01:32:25Z","updated":"2026-09-30T01:32:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een eencentrumobservatiestudie onder 70 bevestigde patiënten met cardiale amyloïdose in Egypte toont een gemiddelde diagnostische vertraging van bijna 12 maanden en een hoge sterfte van 48,6%. AL-amyloïdose was het meest voorkomende subtype, terwijl ATTR slechts 4,3% vertegenwoordigde. De bevindingen benadrukken de urgente behoefte aan verbeterde klinische alertheid en gestroomlijnde diagnostische trajecten om deze zeldzame, maar dodelijke aandoening eerder te herkennen en te behandelen.","abstract_original":"BACKGROUND: Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of insoluble amyloid fibrils. Despite the growing global recognition of cardiac amyloidosis and the recent development of targeted therapeutic strategies for specific amyloidosis subtypes, demographic and epidemiological data regarding cardiac amyloidosis in Egypt remain limited. The aim of the study was to describe the demographic and clinical characteristics of cardiac amyloidosis in Egyptian patients; and to identify the diagnostic challenges associated with cardiac amyloidosis and the disease-related outcomes. RESULTS: Among 84 patients initially evaluated for suspected cardiac amyloidosis at tertiary care facility in Egypt, 70 were confirmed to have the disease. The mean interval from symptom onset to diagnosis was 11.86 months. AL amyloidosis was the most common subtype, followed by AA amyloidosis. ATTR amyloidosis accounted for only 4.3% of cases, while the specific amyloidosis subtype could not be identified in 21.4% of patients. New complications developed in 21.4% of patients, with renal complications being the most common. The study observed a high mortality rate, with 48.6% of patients dying during the study period. CONCLUSIONS: This tertiary care center study of cardiac amyloidosis in Egyptian patients demonstrated a substantial diagnostic delay and poor clinical outcomes. In our study cohort, the most common subtype was AL amyloidosis and nearly half of the study population died during the study period, highlighting the advanced stage of disease at presentation and its grave prognosis. These findings underscore the need for greater clinical awareness, streamlined diagnostic pathways and improved access to comprehensive diagnostic modalities to ensure timely diagnosis and optimal patient care."}